What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It was engineered to replicate the activity of endogenous GHRH — the signal that prompts the pituitary gland to secrete growth hormone. In research, it is examined primarily for how it influences GH regulation and the metabolic pathways connected to it.

What is GHRH?

Growth hormone-releasing hormone (GHRH) is a peptide secreted by the hypothalamus. Its main roles include:

• Triggering growth hormone (GH) release from the pituitary gland

• Contributing to pathways involved in protein and lipid metabolism

• Taking part in cellular signaling tied to growth and recovery

• Helping regulate the circadian patterning of GH release in research settings

Because native GHRH degrades quickly in the body, researchers developed more stable analogues such as Tesamorelin to enable longer-duration study.

How Tesamorelin is Being Studied:

1. Observed Effects on Growth Hormone Secretion

   Tesamorelin binds to GHRH receptors on the pituitary gland, prompting a natural rise in GH output. In laboratory work, this allows researchers to study the downstream effects of elevated GH, including shifts in lipid metabolism and muscle development.

   (Reference: Falutz et al., 2010)

2. Effects on Visceral Adipose Tissue

   One of Tesamorelin’s most-examined effects is its capacity to reduce visceral fat in certain research populations. Across multiple trials, it has been associated with measurable decreases in abdominal fat while leaving subcutaneous fat largely unaffected.

   (Reference: Stanley et al., 2011)

3. Observed Effects on Glucose Pathways

   Whereas some GH-related peptides can disturb glucose metabolism, Tesamorelin has shown little to no impact on insulin sensitivity in certain models, making it a recurring subject of metabolic research.

   (Reference: Guaraldi et al., 2012)

References

• Falutz, J., et al. (2010). Metabolic effects of a growth hormone–releasing factor in patients with HIV. The New England Journal of Medicine, 363(8), 716–726.

• Stanley, T.L., et al. (2011). Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism, 96(9), 2738–2745.

• Guaraldi, G., et al. (2012). Tesamorelin: a growth hormone-releasing factor analogue for management of HIV-associated lipodystrophy. Drugs of Today, 48(11), 745–752.

All products sold by Direct Peptides are strictly for laboratory research purposes only. They are not intended for human or animal consumption, medical, or therapeutic use. The information provided on this website is for educational and informational purposes only.